-transparent.png){kind=logo}
The authors conducted a phase II study of L-alanosine in 39 patients (19 without prior chemotherapy) in advanced malignant melanoma. The intravenous dose was 250 mg/m2/days 1-3 repeated at 3-week intervals. There were two objective regressions (5%) in conjunction with generally transient and tolerable hematologic and gastrointestinal toxicity. L-alanosine as used in our study has limited activity against malignant melanoma.
Related Publications
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
July 1987,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
February 1991,
Investigational new drugs,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
August 1983,
Cancer,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
June 1988,
Investigational new drugs,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
April 1982,
Cancer,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
January 1981,
Cancer treatment reports,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
February 1983,
Cancer,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
July 1986,
Cancer treatment reports,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
January 1980,
Cancer treatment reports,
E T Creagan, and
H J Long, and
D L Ahmann, and
S J Green
January 1980,
Cancer treatment reports,
